Results from the first phase of a phase 1/2 clinical trial with the cancer vaccine, ilixadencel, were published in Journal for ImmunoTherapy of Cancer last week. The study showed that when the vaccine is injected into the tumours of newly diagnosed metastatic kidney cancer patients, it provoked a potent immune response to the disease.
In addition, the median length of time that patients have survived after treatment with ilixadencel was 42.5 months – the median overall survival for patients receiving standard therapy is around 15 months. However, the researchers are still following patients, so survival may increase even further for the patients treated with ilixadencel.
Read the Journal for ImmunoTherapy of Cancer paper here